As TAVI Advances, Adjunctive Devices Multiply
Executive Summary
As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.
You may also be interested in...
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover KCI's shift to private status, J&J's exit from drug-eluting stents, safety concerns about Edwards' Sapien TAVI device, and the MoneyTree 2Q2011 report on medtech venture financings.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.